Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

ArQule

- PMLiVE

ALX Oncology’s evorpacept shows promise as gastric cancer combination treatment

More than 6,500 new diagnoses of gastric cancer are made in the UK every year

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

- PMLiVE

Merck’s Keytruda combination recommended by NICE for advanced gastric cancer

More than 6,500 new cases of gastric cancer are diagnosed in the UK every year

- PMLiVE

AstraZeneca signs exclusive licensing deal worth over $500m for Pinetree’s EGFR degrader

The candidate has shown promising preclinical anti-tumour activity in drug- and TKI-resistant tumours

- PMLiVE

Ipsen gains ex-US rights to Day One’s brain cancer therapy in deal worth over $460m

Paediatric low-grade gliomas are the most common type of brain tumour diagnosed in children

- PMLiVE

Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn

The companies will aim to advance targeted myeloid engager programmes in oncology

- PMLiVE

ICR study on cell competition mechanism could lead to new ways of treating cancer

Female breast, lung, bowel and prostate cancers account for more than four in ten of all cancers worldwide

- PMLiVE

Merck’s investigational RSV monoclonal antibody clesrovimab shown to protect infants

The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

- PMLiVE

Researchers develop AI model to identify breast cancer stages and progression

Up to 50% of ductal carcinoma in situ patients progress to a highly invasive stage of cancer

Bayer symbol

Bayer/Orion’s darolutamide combination shows promise in phase 3 prostate cancer trial

The results from the study will support regulatory applications for wider use of the drug

- PMLiVE

ICR study reveals Lynparza could treat more advanced prostate cancer patients

Up to 30% of men living with the advanced disease have tumours that contain defects in repairing DNA

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links